jnj-77242113,deucravacitinib
janssen,sonnet biotherapeutics,bms
['frontier 1', 'psoriasis', 'sonnet', 'janssen']
interesting results from late breaking session today on an oral il-23 inhibitor peptide for #psoriasis - against the widely perceived problem of gi absorption of effective targeted immunomodulators. a safe competitor to decravacitinib? #wcd2023singapore #wcd2023 
@OfficialUoM Clinical Senior Lecturer in #Dermatology #RxEpi 
@BrJDermatol Associate Editor for Guidelines 
@CochraneSkin Editor

#Psoriasis @BADBIR #GUIDEMAP